Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
Cardiac Hypertrophy Caused by Peroxisome Proliferator Activated Receptor-Gamma
Agonist Treatment Occurs Independently of Changes in Myocardial Insulin
Signaling
Authors
Sandra Sena, Isaac R. Rasmussen, Adam R. Wende, Alfred P. McQueen, Heather A.
Theobald, Nicole Wilde, Renata Oliveira Pereira, Sheldon E. Litwin, Joel P.
Berger, E. Dale Abel
Submitted By
E. Dale Abel on 9/24/2007
Status
Published
Journal
Endocrinology
Year
2007
Date Published
12/1/2007
Volume : Pages
148(12) : 6047 - 6053
PubMed Reference
17823261
Abstract
PPAR-gamma ligands are insulin sensitizers, widely used in the treatment of type
2 diabetes. A consistent observation in preclinical species is the development
of cardiac hypertrophy following short-term treatment with these agents. The
mechanisms for this hypertrophy are incompletely understood. Given the important
role of insulin signaling in the regulation of myocardial size, we tested the
hypothesis that augmentation of myocardial insulin signaling may play a role in
PPAR-gamma ligand-induced cardiac hypertrophy. We treated mice with
cardiomyocyte selective KO of insulin receptors (CIRKO) and littermate controls
(WT), with 2-(2-(4-phenoxy-
2-propylphenoxy) ethyl) indole-5-acetic acid, which is a non-thiazolidinedione
PPAR-gamma agonist (COOH) for 2 weeks. 2-weeks of COOH treatment increased heart
weights by 22% in CIRKO mice and by 16% in WT, and induced similar fold increase
in the expression of hypertrophic markers such as alpha-skeletal actin, BNP and
ANP in CIRKO and WT hearts. COOH treatment increased plasma volume by 10% in
COOH-treated WT and CIRKO mice, but did not increase systolic or diastolic blood
pressure. Echocardiographic analysis was also consistent with volume overload as
evidenced by increased LV diastolic diameters and cardiac output in COOH treated
CIRKO and WT mice. These data indicate that cardiac hypertrophy following
PPAR-gamma agonist treatment can occur in the absence of myocardial insulin
signaling and is likely secondary to the hemodynamic consequences of plasma
volume expansion.
Investigators with authorship
Name
Institution
E. Dale Abel
University of Iowa
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Genes
Symbol
Description
Ppara
peroxisome proliferator activated receptor alpha
Pparg
peroxisome proliferator activated receptor gamma
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!